CN111182880B - Wnt组合物和从无血清培养条件进行的工艺方法 - Google Patents

Wnt组合物和从无血清培养条件进行的工艺方法 Download PDF

Info

Publication number
CN111182880B
CN111182880B CN201880064338.XA CN201880064338A CN111182880B CN 111182880 B CN111182880 B CN 111182880B CN 201880064338 A CN201880064338 A CN 201880064338A CN 111182880 B CN111182880 B CN 111182880B
Authority
CN
China
Prior art keywords
polypeptide
wnt3a
cases
wnt
frizzled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201880064338.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN111182880A (zh
Inventor
袁平
吉尔·赫尔姆斯
朱英
刘波
史蒂芬妮·加斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ankasa Regenerative Therapy Co
Original Assignee
Ankasa Regenerative Therapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ankasa Regenerative Therapy Co filed Critical Ankasa Regenerative Therapy Co
Publication of CN111182880A publication Critical patent/CN111182880A/zh
Application granted granted Critical
Publication of CN111182880B publication Critical patent/CN111182880B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880064338.XA 2017-08-01 2018-08-01 Wnt组合物和从无血清培养条件进行的工艺方法 Expired - Fee Related CN111182880B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762539960P 2017-08-01 2017-08-01
US62/539,960 2017-08-01
US201862630448P 2018-02-14 2018-02-14
US62/630,448 2018-02-14
PCT/US2018/044886 WO2019028186A1 (en) 2017-08-01 2018-08-01 WNT COMPOSITIONS AND METHODS OF TREATMENT FROM SERUM-FREE CULTURE CONDITIONS

Publications (2)

Publication Number Publication Date
CN111182880A CN111182880A (zh) 2020-05-19
CN111182880B true CN111182880B (zh) 2024-01-09

Family

ID=65234165

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880064338.XA Expired - Fee Related CN111182880B (zh) 2017-08-01 2018-08-01 Wnt组合物和从无血清培养条件进行的工艺方法

Country Status (8)

Country Link
US (1) US20200399588A1 (enExample)
EP (1) EP3661475A4 (enExample)
JP (2) JP2020529845A (enExample)
CN (1) CN111182880B (enExample)
AU (1) AU2018309026A1 (enExample)
CA (1) CA3071638A1 (enExample)
GB (2) GB2610090B (enExample)
WO (1) WO2019028186A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019121846A1 (en) * 2017-12-19 2019-06-27 CSL Behring Lengnau AG Protein purification and virus inactivation with alkyl glycosides
CN115702242A (zh) * 2020-04-20 2023-02-14 医药控股公司 一种改性的细菌透明质酸酶多肽、生产方法、药物组合物及其用途
CN116359367B (zh) * 2022-12-27 2023-08-25 绍兴市食品药品检验研究院 一种同位素内标高效液相色谱串联质谱法检测食品中γ-氨基丁酸的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101416058A (zh) * 2004-09-21 2009-04-22 罗德岛医院,终身合伙人 Wnt蛋白及癌症的检测与治疗
CN103998462A (zh) * 2011-09-16 2014-08-20 菲特治疗公司 Wnt组合物及此类组合物的治疗应用
CN104768579A (zh) * 2012-10-23 2015-07-08 昂科梅德制药有限公司 使用Wnt途径结合剂来治疗神经内分泌肿瘤的方法
CN105555297A (zh) * 2013-10-02 2016-05-04 小利兰斯坦福大学托管委员会 Wnt组合物及纯化方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0707472B1 (en) * 1993-07-08 2001-03-14 The Liposome Company, Inc. Method of controlling the size of liposomes
US6610316B2 (en) * 1997-05-30 2003-08-26 Shanbrom Technologies, Llc Disinfection by particle-bound and insolubilized detergents
US20070072239A1 (en) * 2005-09-26 2007-03-29 Wyeth Pharmaceutical compositions and methods of using secreted frizzled related protein
US8431532B2 (en) * 2010-06-28 2013-04-30 Five Prime Therepeutics, Inc. FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same
JP7150604B2 (ja) * 2016-01-28 2022-10-11 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 無血清合成のためのｗｎｔ組成物及び方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101416058A (zh) * 2004-09-21 2009-04-22 罗德岛医院,终身合伙人 Wnt蛋白及癌症的检测与治疗
CN103998462A (zh) * 2011-09-16 2014-08-20 菲特治疗公司 Wnt组合物及此类组合物的治疗应用
CN104768579A (zh) * 2012-10-23 2015-07-08 昂科梅德制药有限公司 使用Wnt途径结合剂来治疗神经内分泌肿瘤的方法
CN105555297A (zh) * 2013-10-02 2016-05-04 小利兰斯坦福大学托管委员会 Wnt组合物及纯化方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Active and water-soluble form oflipidated Wnt protein is maintained by aserum glycoprotein afamin/α-albumin";Emiko Mihara等;《Elife》;20160223(第5期);第1页摘要，第2页第6段，第11页第2段、第9页第3段 *
"Biochemical characterization of Wnt-Frizzled interactions using asoluble, biologically active vertebrate Wnt protein";JEN-CHIHHSIEH等;《PANS》;19990331;第96卷(第7期);摘要 *
Emiko Mihara等."Active and water-soluble form oflipidated Wnt protein is maintained by aserum glycoprotein afamin/α-albumin".《Elife》.2016,(第5期),第1-19页. *
余元勋等.Wnt信号通路与疾病.《中国分子骨质疏松症学》.安徽科学技术出版社,2016,第103页. *
刘粤酶等.常用缓冲液及酸碱指示剂.《生物化学实验教程》.人民卫生出版社,1997,第150页. *
罗云波等."下游工程案例".《食品生物技术导论》.化学工业出版社,2006,第271页. *

Also Published As

Publication number Publication date
AU2018309026A1 (en) 2020-03-12
GB2581882A (en) 2020-09-02
GB202216232D0 (en) 2022-12-14
CN111182880A (zh) 2020-05-19
GB2610090B (en) 2023-05-17
GB2581882B (en) 2023-03-29
EP3661475A4 (en) 2021-06-02
JP2024120178A (ja) 2024-09-04
US20200399588A1 (en) 2020-12-24
GB2610090A (en) 2023-02-22
CA3071638A1 (en) 2019-02-07
GB202001567D0 (en) 2020-03-18
EP3661475A1 (en) 2020-06-10
WO2019028186A1 (en) 2019-02-07
JP2020529845A (ja) 2020-10-15

Similar Documents

Publication Publication Date Title
JP2024120178A (ja) Ｗｎｔ組成物および無血清培養条件からの処理の方法
JP2020506701A (ja) 組織特異的Ｗｎｔシグナル増強分子およびその使用
AU2018200971A1 (en) Protein expression enhancing polypeptides
KR20150114512A (ko) 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US20220325238A1 (en) Wnt compositions and methods for serum-free synthesis
WO2014000042A1 (en) COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS
KR102392423B1 (ko) Wnt 조성물 및 정제 방법
JP7600135B2 (ja) 組換えｃｃｎドメインタンパク質および融合タンパク質
JP2018502908A (ja) アルファ‐１‐ アンチトリプシン（ａ１ａｔ）融合タンパク質及びその使用
WO2023086790A1 (en) Method for producing an antibody peptide conjugate
CN114945588A (zh) 抗缪勒氏管激素多肽
CN115244076A (zh) Gdf15融合蛋白及其用途
AU2004276687B2 (en) Method of cleaving polypeptide by using OmpT protease mutant
WO2020018445A1 (en) Frizzled specific wnt agonists and antagonists
RU2825102C2 (ru) Рекомбинантные белки с доменами ccn и слитые белки

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20240109